Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer

2020516 citationsJournal Articlehybrid Open Access

Authors

Vicky Makker · Memorial Sloan Kettering Cancer Center

Matthew H. Taylor · Oregon Health & Science University

Carol Aghajanian · Memorial Sloan Kettering Cancer Center

Ana Oaknin · Vall d'Hebron Hospital Universitari

James W. Mier · Beth Israel Deaconess Medical Center

Allen Lee Cohn · Rocky Mountain Cancer Centers

Margarita Romeo

Abstract

Lenvatinib plus pembrolizumab showed promising antitumor activity in patients with advanced endometrial carcinoma who have experienced disease progression after prior systemic therapy, regardless of tumor MSI status. The combination therapy had a manageable toxicity profile.

Topics & Keywords

Endometrial and Cervical Cancer Treatments Cancer Immunotherapy and Biomarkers Ovarian cancer diagnosis and treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 38, Issue 26, pp. 2981-2992

DOI: 10.1200/jco.19.02627

Field-Weighted Citation Impact: 37.40